Four drugs for treating various stages of kidney cancer have been turned down for health service funding in England, in spite of price cuts by the manufacturers.

The decisions by the National Institute for Clinical Excellence underline that new guidance last year for “end of life” treatments will not produce a wave of new approvals for costly drugs that can extend life but where there is not yet evidence of dramatic results.